Barbara H McGovern
7PUBLICATIONS
1CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Oct 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.Timothy J Straub, Mary-Jane Lombardo, Jessica A Bryant
|Aug 04, 2023
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.Christopher W J McChalicher, Mary-Jane Lombardo, Sahil Khanna
|Aug 04, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Charles S Berenson, Bret Lashner, Louis Y Korman
|Sep 26, 2022
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.Christopher McChalicher, Ahmad Abdulaziz, S Steve Zhou
|Jan 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.Paul Feuerstadt, Thomas J Louie, Bret Lashner
|May 15, 2020
The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.Mark H Wilcox, Barbara H McGovern, Gail A Hecht
Pageof 2
